Finally, in Aim 3, we will develop and validate predictive tumor, immunological and imaging biomarkers of response in recurrent glioblastoma patients enrolled in a Phase II clinical trial of DCVax-L +/- PD-1 blockade.
Amazing you went through that whole discussion only to in the end admit the poster was right that UCLA is not using DCVax. I think everybody knows that NWBO owns the DCVax name. The question is why isn't UCLA using it?
We are now five months since they announced data lock, and we haven't heard a word since. Every single person in the world knows for a fact that if they had something good to report they wouldn't have sat on it for five months. Everybody knows that. All of your and Dr. Bala's supposedly thorough research and due diligence would be a lot more valuable if you guys would start asking some legitimate questions about what is really going on here instead of playing company propagandists every time. If shareholders would finally stand up to the liars running this company maybe we wouldn't be jerked around like this.